Shire (NASDAQ:SHPG)‘s stock had its “buy” rating reiterated by equities researchers at Royal Bank Of Canada in a report issued on Thursday, November 16th.
SHPG has been the topic of a number of other reports. Piper Jaffray Companies set a $159.00 price target on Shire and gave the stock a “hold” rating in a research note on Wednesday, July 26th. ValuEngine cut Shire from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a research note on Friday, October 27th. Cantor Fitzgerald reiterated a “buy” rating and issued a $222.00 price objective on shares of Shire in a research note on Friday, October 27th. Finally, Liberum Capital upgraded Shire from a “hold” rating to a “buy” rating in a research note on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. Shire currently has a consensus rating of “Hold” and an average price target of $212.18.
Shares of Shire (NASDAQ SHPG) traded down $2.91 during trading on Thursday, reaching $145.34. The company had a trading volume of 780,609 shares, compared to its average volume of 1,140,259. The stock has a market capitalization of $44,538.30, a price-to-earnings ratio of 10.20, a price-to-earnings-growth ratio of 0.82 and a beta of 1.59. Shire has a 52 week low of $137.17 and a 52 week high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55.
Shire (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.64 by $0.17. Shire had a return on equity of 14.41% and a net margin of 10.95%. The company had revenue of $3.70 billion during the quarter. During the same quarter in the previous year, the company posted $3.17 earnings per share. The company’s revenue was up 7.1% on a year-over-year basis. equities research analysts predict that Shire will post 15 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the business. Hartford Financial Management Inc. grew its holdings in shares of Shire by 5.4% during the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 32 shares during the last quarter. YorkBridge Wealth Partners LLC grew its holdings in shares of Shire by 81.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 317 shares during the last quarter. BB&T Investment Services Inc. grew its holdings in shares of Shire by 1,672.3% during the third quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 786 shares during the last quarter. Pacer Advisors Inc. purchased a new position in shares of Shire during the second quarter worth about $171,000. Finally, Steward Partners Investment Advisory LLC purchased a new position in shares of Shire during the third quarter worth about $159,000. Institutional investors own 20.28% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2017/12/04/shire-plcs-shpg-buy-rating-reiterated-at-royal-bank-of-canada.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.